Proposed future directions for research on the field of CXCR1 and 2 inhibition in the context of acute respiratory distress syndrome and unanswered questions on CXCR1/2 inhibitors
| Future research focus | Unanswered questions |
|---|---|
| Timing | Early versus late disease administration |
| Preferential focus on type of receptor | CXCR1 versus CXCR2 versus CXCR1/2 inhibitors |
| Severity of disease | Mild/moderate versus severe disease administration |
| Heterogeneity of disease | “Hyper” versus “hypo” inflammatory phenotype and how to define them (i.e. systemic versus alveolar inflammatory markers) |
| Mode of administration | Systemic versus localised to the lung versus combined administration |
| Duration of treatment | Short term versus prolonged treatment and preservation of balance between harmful and beneficial neutrophilic effects |
| Effect on other cell types | Focus on endothelial and epithelial cell specific CXCR1/2 inhibition |
| Treatment combinations | Combinations with other neutrophilic receptor blockers or pulmonary oedema clearing drugs |